In our chosen profession, patients come first. For care to be optimized, work environments need to be safe and supportive. We believe this is possible through productive discussions held in good faith between a workforce and its employers, to reach a fair and much-needed resolution to the grievances of America’s pharmacists.

Our profession is experiencing unprecedented rates of burnout and even a great migration of oncology pharmacists away from patient care roles. This problem is so endemic that HOPA has established a Wellness Task Force to help combat burnout among our members. And still, more can be done.

We know that addressing the wide, systemic concerns among pharmacists, pharmacy technicians, and other healthcare workers does not come with a simple solution. But we also know pharmacists and pharmacies have a shared goal of providing the best patient care possible.

Some initial promising steps have been taken, and we hope this continues for the good of patient care. We support all pharmacists, regardless of setting or specialty, and hope for a swift and satisfactory resolution to industrial actions being taken today.

Advocacy

Oncology Experts Join Together to Provide Best Possible Care for Adolescents and Young Adults with Cancer

The Hematology/Oncology Pharmacy Association (HOPA) has partnered with Stupid Cancer, the leader in young adult cancer advocacy, research, and support, to develop tools for healthcare providers who serve the adolescent and young adult (AYA) patient commun

Pharmacist talking to a customer
Advocacy

The Value of Oncology Pharmacists Op-Ed

With Drug Shortages and Errors on the Rise, Oncology Pharmacists are Vital to Navigate Treatment in the Era of a Pandemic

Pharmacist talking to a customer
Advocacy

The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling

The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens